Enliven Therapeutics, Inc.
ELVN
$58.82
$0.761.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.49% | 20.36% | -47.25% | 20.47% | 11.24% |
| Total Depreciation and Amortization | -50.00% | -69.57% | -25.81% | -23.46% | 9.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 87.62% | -38.27% | 80.41% | -11.67% | 15.28% |
| Change in Net Operating Assets | 82.38% | -381.71% | 876.43% | -150.16% | 112.54% |
| Cash from Operations | 3.94% | -21.80% | -19.27% | 22.15% | 29.30% |
| Capital Expenditure | -- | -- | -100.00% | 100.72% | -595.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,138.11% | 249.55% | 399.73% | 97.79% | -12,777.95% |
| Cash from Investing | -1,138.34% | 243.53% | 405.05% | 97.79% | -12,965.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,509.75% | 1,294.31% | -- | -- | 93,223.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 17.65% | -- | -- |
| Cash from Financing | 4,509.75% | 1,513.64% | 269.29% | -100.17% | 93,223.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -90.02% | 1,273.77% | 83.98% | -199.85% | 178.93% |